Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Trial Profile

Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 May 2018

At a glance

  • Drugs Ilodecakin (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ARTIST 1; Sequoia
  • Sponsors ARMO Biosciences
  • Most Recent Events

    • 26 Mar 2018 According to an ARMO BioSciences media release, after completion of first interim analysis (n=60), the Data Monitoring Committee (DMC) has recommended continue study without modification. As of March 15th of this year, 178 patients have been randomized, and the second interim analysis and the final data analysis are expected in 2020.
    • 09 Oct 2017 According to an ARMO BioSciences media release, Joseph Leveque, M.D. will lead this trial.
    • 20 Apr 2017 According to an ARMO BioSciences media release, results from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top